Search

Your search keyword '"Orosa-Vázquez, Ivette"' showing total 8 results
Start Over Author "Orosa-Vázquez, Ivette"
8 results on '"Orosa-Vázquez, Ivette"'

1. Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children

Author

Mesa-Herrera, María Elena, García-Cristiá, Yarmila, Verdecia-Sánchez, Leonor, del Valle Rodríguez, Rafael, Oquendo-de la Cruz, Yudalvies, Álvarez-Montalvo, Daysi, Grillo-Fortún, Randy, López-González, Liset, Galindo, Omaida Fonte, Reyes-González, Yeseni, González-Álvarez, Ana Beatriz, Gorrita-Mora, Linet, Valera-Fernández, Rodrigo, Ontivero-Pino, Ivis, Martínez-Pérez, Marisel, Caballero-Gonzalez, Esperanza, Garcés-Hechavarría, Aniurka, Martínez-Bedoya, Dayle, Medina-Nápoles, Maite, Domínguez-Pentón, Yeney Regla, Cazañas-Quintana, Yadira, Barrios, Thais Fundora, Fernández, Diana R. Hernández, Bergado-Báez, Gretchen, Orosa-Vazquez, Ivette, Pi-Estopiñan, Franciscary, Díaz-Hernández, Marianniz, Cruz-Sui, Otto, Noa-Romero, Enrique, García-López, Arilia, Muro, Sandra Rivadereira, Baro-Roman, Gerardo, Puga-Gómez, Rinaldo, Ricardo-Delgado, Yariset, Rojas-Iriarte, Chaumey, Céspedes-Henriquez, Leyanis, Piedra-Bello, Misleidys, Vega-Mendoza, Dania, Pérez, Noelvia Pestana, Paredes-Moreno, Beatriz, Rodríguez-González, Meiby, Valenzuela-Silva, Carmen, Sánchez-Ramírez, Belinda, Rodríguez-Noda, Laura, Pérez-Nicado, Rocmira, González-Mugica, Raul, Hernández-García, Tays, Fundora-Barrios, Talía, Echevarría, Martha Dubet, Enriquez-Puertas, Juliet María, Infante-Hernández, Yenicet, Palenzuela-Díaz, Ariel, Gato-Orozco, Evelyn, Chappi-Estévez, Yanet, Francisco-Pérez, Julio Cesar, Suarez-Martinez, Miladi, Castillo-Quintana, Ismavy C., Fernandez-Castillo, Sonsire, Climent-Ruiz, Yanet, Santana-Mederos, Darielys, García-Vega, Yanelda, Toledo-Romani, María Eugenia, Doroud, Delaram, Biglari, Alireza, Valdés-Balbín, Yury, García-Rivera, Dagmar, and Vérez-Bencomo, Vicente

Published
2023
Full Text
View/download PDF

2. Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

Author

Cubas-Curbelo, Mailin, Rodríguez-Castillo, Pedro Gabriel, Acevedo-Martínez, Yosmel, Estoque-Cabrera, Solangel, Ávila-Cabreja, José Alejandro, Alfaro-Guzmán, Ainadis, Zulueta-Pérez, Lilian, Espino-Rojas, Niurka Tamara, Medinas-Santos, Gloria Margarita, Sarda-Rodriguez, Ileana Luisa, Acosta-Martinez, Mario Alejandro, Reyes-Matienzo, Radamet, Coviella-Artime, José Manuel, Morffi-Cinta, Irania, Martínez-Pérez, Marisel, Valera-Fernández, Rodrigo, Garcés-Hechavarría, Aniurka, Martínez-Bedoya, Dayle, Garrido-Arteaga, Raine, Cardoso-SanJorge, Félix, Ramírez-Gonzalez, Ubel, Quintero-Moreno, Lauren, Ontivero-Pino, Ivis, Martínez-Rivera, Roselyn, Guillén-Obregón, Berta, Lora-García, Janet, Medina-Nápoles, Maite, Espi-Ávila, Jennifer, Fontanies-Fernández, Marcos, Domínguez-Pentón, Yeney Regla, Bergado-Baez, Gretchen, Pi-Estopiñán, Franciscary, Ojito-Magaz, Eduardo, Rodríguez, Misladys, Cruz-Sui, Otto, García-Montero, Majela, Dubed-Echevarría, Marta, García-López, Elena, Galano-Frutos, Evelyn, Perez-Perez, Alina, Morales-Ruano, Susana, Brito-Pascual, Idalmis, Amoroto, Maité, Arteaga-García, Amaylid, Toledo-Romani, María Eugenia, García-Carmenate, Mayra, Verdecia-Sánchez, Leslyhana, Pérez-Rodríguez, Suzel, Rodriguez-González, Meybis, Valenzuela-Silva, Carmen, Paredes-Moreno, Beatriz, Sanchez-Ramirez, Belinda, González-Mugica, Raúl, Hernández-Garcia, Tays, Orosa-Vázquez, Ivette, Díaz-Hernández, Marianniz, Pérez-Guevara, María Teresa, Enriquez-Puertas, Juliet, Noa-Romero, Enrique, Palenzuela-Diaz, Ariel, Baro-Roman, Gerardo, Mendoza-Hernández, Ivis, Muñoz, Yaima, Gómez-Maceo, Yanet, Santos-Vega, Bertha Leysi, Fernandez-Castillo, Sonsire, Climent-Ruiz, Yanet, Rodríguez-Noda, Laura, Santana-Mederos, Darielys, García-Vega, Yanelda, Chen, Guang-Wu, Doroud, Delaram, Biglari, Alireza, Boggiano-Ayo, Tammy, Valdés-Balbín, Yury, Rivera, Daniel G., García-Rivera, Dagmar, and Vérez-Bencomo, Vicente

Published
2022
Full Text
View/download PDF

3. Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial

Author

Ochoa-Azze, Rolando, Chang-Monteagudo, Arturo, Climent-Ruiz, Yanet, Macías-Abraham, Consuelo, Valenzuela-Silva, Carmen, de los Ángeles García-García, María, Jerez-Barceló, Yanet, Triana-Marrero, Yenisey, Ruiz-Villegas, Laura, Dairon Rodríguez-Prieto, Luis, Guerra-Chaviano, Pedro Pablo, Sánchez-Ramírez, Belinda, Hernández-García, Tays, Orosa-Vázquez, Ivette, Díaz-Hernández, Marianniz, Chiodo, Fabrizio, Calcagno, Andrea, Ghisetti, Valeria, Rodríguez-Acosta, Mireida, Noa-Romero, Enrique, Enríquez-Puertas, Juliet, Ortega-León, Darién, Valdivia-Álvarez, Irinia, Delahanty-Fernández, Aurora, Palenzuela-Díaz, Ariel, Rodríguez-Noda, Laura, González-Mugica, Raúl, Valdés-Balbín, Yury, García-Rivera, Dagmar, and Verez-Bencomo, Vicente

Published
2022
Full Text
View/download PDF

4. Studying the Humoral Response against SARS‐CoV‐2 in Cuban COVID‐19 Recovered Patients.

Author

Orosa Vázquez, Ivette, Díaz, Marianniz, Zúñiga Rosales, Yaima, Amada, Klayris, Chang, Janoi, Relova Hernández, Ernesto, Tundidor, Yaima, Roblejo Balbuena, Hilda, Monzón, Giselle, Torres Rives, Bárbara, Noa Romero, Enrique, Carrillo Valdés, Danay, Valdivia Álvarez, Irinia, Delahanty Fernández, Aurora, Díaz, Claudia, Solozabal, Joaquín, Gil, Mileidys, Sánchez, Belinda, Rojas, Gertrudis, and Marcheco, Beatriz

Subjects
*ANTIBODY formation, *CONVALESCENT plasma, *HUMORAL immunity, *IMMUNE response, *HUMAN skin color
Abstract

Understanding the immune response generated by SARS‐CoV‐2 is critical for assessing efficient therapeutic protocols and gaining insights into the durability of protective immunity. The current work was aimed at studying the specific humoral responses against SARS‐CoV‐2 in Cuban COVID‐19 convalescents. We developed suitable tools and methods based on ELISA methodology, for supporting this evaluation. Here, we describe the development of an ELISA for the quantification of anti‐RBD IgG titers in a large number of samples and a similar test in the presence of NH4SCN as chaotropic agent for estimating the RBD specific antibody avidity. Additionally, a simple and rapid ELISA based on antibody‐mediated blockage of the binding RBD‐ACE2 was implemented for detecting, as a surrogate of conventional test, the levels of anti‐RBD inhibitory antibodies in convalescent sera. In a cohort of 273 unvaccinated convalescents, we identified higher anti‐RBD IgG titer (1 : 1,330, p < 0.0001) and higher levels of inhibitory antibodies blocking RBD‐ACE2 binding (1 : 216, p < 0.05) among those who had recovered from severe illness. Our results suggest that disease severity, and not demographic features such as age, sex, and skin color, is the main determinant of the magnitude and neutralizing ability of the anti‐RBD antibody response. An additional paired longitudinal assessment in 14 symptomatic convalescents revealed a decline in the antiviral antibody response and the persistence of neutralizing antibodies for at least 4 months after the onset of symptoms. Overall, SARS‐CoV‐2 infection elicits different levels of antibody response according to disease severity that declines over time and can be monitored using our homemade serological assays. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial

Author

Chang-Monteagudo, Arturo, Ochoa-Azze, Rolando, Climent-Ruiz, Yanet, Macías-Abraham, Consuelo, Rodríguez-Noda, Laura, Valenzuela-Silva, Carmen, Sánchez-Ramírez, Belinda, Perez-Nicado, Rocmira, Hernández-García, Tays, Orosa-Vázquez, Ivette, Díaz-Hernández, Marianniz, García-García, María de los Ángeles, Jerez-Barceló, Yanet, Triana-Marrero, Yenisey, Ruiz-Villegas, Laura, Rodríguez-Prieto, Luis Dairon, Puga-Gómez, Rinaldo, Guerra-Chaviano, Pedro Pablo, Zúñiga-Rosales, Yaíma, Marcheco-Teruel, Beatriz, Rodríguez-Acosta, Mireida, Noa-Romero, Enrique, Enríquez-Puertas, Juliet, Porto-González, Delia, Fernández-Medina, Olivia, Valdés-Zayas, Anet, Chen, Guang-Wu, Herrera-Martínez, Luís, Valdés-Balbín, Yury, García-Rivera, Dagmar, and Verez-Bencomo, Vicente

Published
2021
Full Text
View/download PDF

6. Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

Author

Toledo-Romani, María Eugenia, primary, García-Carmenate, Mayra, additional, Verdecia-Sánchez, Leslyhana, additional, Pérez-Rodríguez, Suzel, additional, Rodriguez-González, Meybis, additional, Valenzuela-Silva, Carmen, additional, Paredes-Moreno, Beatriz, additional, Sanchez-Ramirez, Belinda, additional, González-Mugica, Raúl, additional, Hernández-Garcia, Tays, additional, Orosa-Vázquez, Ivette, additional, Díaz-Hernández, Marianniz, additional, Pérez-Guevara, María Teresa, additional, Enriquez-Puertas, Juliet, additional, Noa-Romero, Enrique, additional, Palenzuela-Diaz, Ariel, additional, Baro-Roman, Gerardo, additional, Mendoza-Hernández, Ivis, additional, Muñoz, Yaima, additional, Gómez-Maceo, Yanet, additional, Santos-Vega, Bertha Leysi, additional, Fernandez-Castillo, Sonsire, additional, Climent-Ruiz, Yanet, additional, Rodríguez-Noda, Laura, additional, Santana-Mederos, Darielys, additional, García-Vega, Yanelda, additional, Chen, Guang-Wu, additional, Doroud, Delaram, additional, Biglari, Alireza, additional, Boggiano-Ayo, Tammy, additional, Valdés-Balbín, Yury, additional, Rivera, Daniel G., additional, García-Rivera, Dagmar, additional, Vérez-Bencomo, Vicente, additional, Cubas-Curbelo, Mailin, additional, Rodríguez-Castillo, Pedro Gabriel, additional, Acevedo-Martínez, Yosmel, additional, Estoque-Cabrera, Solangel, additional, Ávila-Cabreja, José Alejandro, additional, Alfaro-Guzmán, Ainadis, additional, Zulueta-Pérez, Lilian, additional, Espino-Rojas, Niurka Tamara, additional, Medinas-Santos, Gloria Margarita, additional, Sarda-Rodriguez, Ileana Luisa, additional, Acosta-Martinez, Mario Alejandro, additional, Reyes-Matienzo, Radamet, additional, Coviella-Artime, José Manuel, additional, Morffi-Cinta, Irania, additional, Martínez-Pérez, Marisel, additional, Valera-Fernández, Rodrigo, additional, Garcés-Hechavarría, Aniurka, additional, Martínez-Bedoya, Dayle, additional, Garrido-Arteaga, Raine, additional, Cardoso-SanJorge, Félix, additional, Ramírez-Gonzalez, Ubel, additional, Quintero-Moreno, Lauren, additional, Ontivero-Pino, Ivis, additional, Martínez-Rivera, Roselyn, additional, Guillén-Obregón, Berta, additional, Lora-García, Janet, additional, Medina-Nápoles, Maite, additional, Espi-Ávila, Jennifer, additional, Fontanies-Fernández, Marcos, additional, Domínguez-Pentón, Yeney Regla, additional, Bergado-Baez, Gretchen, additional, Pi-Estopiñán, Franciscary, additional, Ojito-Magaz, Eduardo, additional, Rodríguez, Misladys, additional, Cruz-Sui, Otto, additional, García-Montero, Majela, additional, Dubed-Echevarría, Marta, additional, García-López, Elena, additional, Galano-Frutos, Evelyn, additional, Perez-Perez, Alina, additional, Morales-Ruano, Susana, additional, Brito-Pascual, Idalmis, additional, Amoroto, Maité, additional, and Arteaga-García, Amaylid, additional

Published
2022
Full Text
View/download PDF

7. Safety and Immunogenicity of Anti-SARS-CoV-2 Conjugate Vaccine SOBERANA 02: Phase IIb Clinical Trial

Author

Eugenia-Toledo-Romani, Maria, primary, García Carmenate, Mayra, additional, Verdecia-Sánchez, Leslyhana, additional, Pérez-Rodríguez, Suzel, additional, Rodriguez-González, Meiby, additional, Valenzuela-Silva, Carmen, additional, Paredes-Moreno, Beatriz, additional, Sánchez-Ramírez, Belinda, additional, González-Mugica, Raul, additional, Hernández-García, Tays, additional, Orosa-Vázquez, Ivette, additional, Díaz-Hernández, Marianniz, additional, Pérez-Guevara, María Teresa, additional, Enríquez-Puertas, Juliet, additional, Noa-Romero, Enrique, additional, Palenzuela-Diaz, Ariel, additional, Baro-Roman, Gerardo, additional, Mendoza-Hernández, Ivis, additional, Muñoz, Yaima, additional, Gómez-Maceo, Yanet, additional, Santos Vega, Bertha Leysi, additional, Fernandez-Castillo, Sonsire, additional, Climent-Ruiz, Yanet, additional, Rodríguez-Noda, Laura, additional, Santana-Mederos, Darielys, additional, García-Vega, Yanelda, additional, Wu-Chen, Guang, additional, Doroud, Delaram, additional, Biglari, Alireza, additional, Boggiano-Ayo, Tammy, additional, Valdés-Balbín, Yury, additional, Rivera, Daniel G., additional, García-Rivera, Dagmar, additional, Verez-Bencomo, Vicente, additional, and Group, SOBERANA Research, additional

Published
2022
Full Text
View/download PDF

8. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.

Author

Eugenia-Toledo-Romaní M, Verdecia-Sánchez L, Rodríguez-González M, Rodríguez-Noda L, Valenzuela-Silva C, Paredes-Moreno B, Sánchez-Ramírez B, Pérez-Nicado R, González-Mugica R, Hernández-García T, Bergado-Baez G, Pi-Estopiñán F, Cruz-Sui O, Fraga-Quintero A, García-Montero M, Palenzuela-Díaz A, Baró-Román G, Mendoza-Hernández I, Fernandez-Castillo S, Climent-Ruiz Y, Santana-Mederos D, Ramírez Gonzalez U, García-Vega Y, Pérez-Massón B, Guang-Wu-Chen, Boggiano-Ayo T, Ojito-Magaz E, Rivera DG, Valdés-Balbín Y, García-Rivera D, Vérez-Bencomo V, Gómez-Maceo Y, Reyes-Matienzo R, Manuel Coviella-Artime J, Morffi-Cinta I, Martínez-Pérez M, Castillo-Quintana I, Garcés-Hechavarría A, Valera-Fernández R, Martínez-Bedoya D, Garrido-Arteaga R, Cardoso-SanJorge F, Quintero Moreno L, Ontivero-Pino I, Teresa Pérez-Guevara M, Morales-García M, Noa-Romero E, Orosa-Vázquez I, Díaz-Hernández M, Rojas G, Tundidor Y, García-López E, Muñoz-Morejon Y, Galano-Frutos E, Rodríguez-Alvarez J, Arteaga A, Medina Nápoles M, Espi Ávila J, and Fontanies Fernández M

Subjects
Adult, Aged, Aged, 80 and over, Antibodies, Neutralizing, Antibodies, Viral, Humans, Immunization, Passive, Immunogenicity, Vaccine, Immunoglobulin G, Middle Aged, SARS-CoV-2, Young Adult, COVID-19 Serotherapy, COVID-19 prevention & control, COVID-19 therapy, COVID-19 Vaccines adverse effects
Abstract

Background: SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report safety and immunogenicity from phase I and IIa clinical trials using two-doses of SOBERANA 02 and three-doses (homologous) or heterologous (with SOBERANA Plus) protocols., Method: We performed an open-label, sequential and adaptive phase I to evaluate safety and explore the immunogenicity of SOBERANA 02 in two formulations (15 or 25 μg RBD-conjugated to 20 μg of TT) in 40 subjects, 19-59-years-old. Phase IIa was open-label including 100 volunteers 19-80-years, receiving two doses of SOBERANA 02-25 μg. In both trials, half of volunteers were selected to receive a third dose of the corresponding SOBERANA 02 and half received a heterologous dose of SOBERANA Plus. Primary outcome was safety. The secondary outcome was immunogenicity evaluated by anti-RBD IgG ELISA, molecular neutralization of RBD:hACE2 interaction, live-virus-neutralization and specific T-cells response., Results: The most frequent adverse event (AE) was local pain, other AEs had frequencies ≤ 5%. No serious related-AEs were reported. Phase IIa confirmed the safety in 60 to 80-years-old subjects. In phase-I SOBERANA 02-25 µg elicited higher immune response than SOBERANA 02-15 µg and progressed to phase IIa. Phase IIa results confirmed the immunogenicity of SOBERANA 02-25 µg even in 60-80-years. Two doses of SOBERANA02-25 µg elicited an immune response similar to that of the Cuban Convalescent Serum Panel and it was higher after the homologous and heterologous third doses. The heterologous scheme showed a higher immunological response. Anti-RBD IgG neutralized the delta variant in molecular assay, with a 2.5-fold reduction compared to D614G neutralization., Conclusions: SOBERANA 02 was safe and immunogenic in persons aged 19-80 years, eliciting neutralizing antibodies and specific T-cell response. Highest immune responses were obtained in the heterologous three doses protocol., Trial Registry: https://rpcec.sld.cu/trials/RPCEC00000340, https://rpcec.sld.cu/trials/RPCEC00000347., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [The Finlay Vaccine Institute, the Centre of Molecular Immunology and the University of Havana have filed patent applications related to the vaccine SOBERANA 02. The authors declare the following competing financial interest(s): L.R.N, B.S.R, R.P.N, S.F.C, Y.C.R, D.S.M, U.R.G, T.B.A, E.O.M, D.G.R, Y.V.B., D.G.R, V.V.B are co-inventors on provisional SARS-CoV-2 vaccine patents (Cu 2020-69). The rest of the authors declare no competing interests. No authors received an honorarium for this paper.], (Copyright © 2022 Elsevier Ltd. All rights reserved.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results